1980-1986. Considering the similarities between the clinical and immunological aspects of leprosy and leishmaniasis plus the success of the leprosy vaccine, Dr. Convit describes a similar highly effective immunotherapy (vaccine) for Cutaneous Leishmaniasis.
1987. Publishes the final description of an immunotherapy against localized Cutaneous Leishmaniasis. Shortly after, he registers this immunotherapy in the Sanitary Ministry of Venezuela for its mass production and distribution to specialized treatment centers throughout the country.
1989. The immunotherapy against American Cutaneous Leishmaniasis is used as a treatment for all localized, intermediate and diffuse forms of the disease.

Terms of Use          Privacy Policy